

Taiwan's Formosa Pharma and Singapore Eye Research Institute partner to advance novel ophthalmic formulations for corneal diseases

May 1, 2026 | News

Collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases



Taiwan-based Formosa Pharmaceuticals, Inc. and the Singapore Eye Research Institute (SERI) have announced a strategic research collaboration to develop next-generation ophthalmic formulations.

This partnership will leverage Formosa's proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI's world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD.

The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice.

Formosa Pharmaceuticals' APNT® platform specialises in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs.